These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24328536)

  • 21. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer.
    Lassen P; Eriksen JG; Hamilton-Dutoit S; Tramm T; Alsner J; Overgaard J;
    Radiother Oncol; 2010 Jan; 94(1):30-5. PubMed ID: 19910068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.
    Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Castro A; Licitra L; Adelstein D; Vermorken JB
    Oncologist; 2017 Sep; 22(9):1056-1066. PubMed ID: 28533474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperfractionated radiotherapy with concurrent docetaxel for advanced head and neck cancer: a phase II study.
    Karasawa K; Matsumoto F; Ito S; Oba S; Furuya T; Hirowatari H; Izawa H; Ito K; Sasai K
    Anticancer Res; 2012 Sep; 32(9):4013-8. PubMed ID: 22993352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nimorazole as a hypoxic radiosensitizer in the treatment of supraglottic larynx and pharynx carcinoma. First report from the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85.
    Overgaard J; Sand Hansen H; Lindeløv B; Overgaard M; Jørgensen K; Rasmusson B; Berthelsen A
    Radiother Oncol; 1991; 20 Suppl 1():143-9. PubMed ID: 2020763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of a 15-gene hypoxia classifier in head and neck cancer for prospective use in clinical trials.
    Toustrup K; Sørensen BS; Metwally MA; Tramm T; Mortensen LS; Overgaard J; Alsner J
    Acta Oncol; 2016; 55(9-10):1091-1098. PubMed ID: 27161763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of adding concomitant chemotherapy to hyperfractionated accelerated radiotherapy for advanced head-and-neck squamous cell carcinoma.
    Nuyts S; Dirix P; Clement PM; Poorten VV; Delaere P; Schoenaers J; Hermans R; Van den Bogaert W
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1088-95. PubMed ID: 18707823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells.
    Sørensen BS; Busk M; Olthof N; Speel EJ; Horsman MR; Alsner J; Overgaard J
    Radiother Oncol; 2013 Sep; 108(3):500-5. PubMed ID: 23953409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94).
    Ghadjar P; Simcock M; Studer G; Allal AS; Ozsahin M; Bernier J; Töpfer M; Zimmermann F; Betz M; Glanzmann C; Aebersold DM;
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):524-31. PubMed ID: 21300466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypoxia-guided adaptive radiation dose escalation in head and neck carcinoma: a planning study.
    Servagi-Vernat S; Differding S; Sterpin E; Hanin FX; Labar D; Bol A; Lee JA; Grégoire V
    Acta Oncol; 2015 Jul; 54(7):1008-16. PubMed ID: 25562382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer.
    Bernier J; Stratford MR; Denekamp J; Dennis MF; Bieri S; Hagen F; Kocagöncü O; Bolla M; Rojas A
    Radiother Oncol; 1998 Aug; 48(2):123-33. PubMed ID: 9783883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of cumulative dose of cisplatin on outcome of patients with head and neck squamous cell carcinoma.
    Al-Mamgani A; de Ridder M; Navran A; Klop WM; de Boer JP; Tesselaar ME
    Eur Arch Otorhinolaryngol; 2017 Oct; 274(10):3757-3765. PubMed ID: 28755023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comment on: A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the the Danish Head and Neck Cancer Study (DAHNCA) Protocol 5-85.
    Ben-Josef E
    Radiother Oncol; 1998 Sep; 48(3):344-6. PubMed ID: 9925257
    [No Abstract]   [Full Text] [Related]  

  • 33. Concomitant adjuvant chemoradiotherapy with weekly low-dose cisplatin for high-risk squamous cell carcinoma of the head and neck: a phase II prospective trial.
    Rampino M; Ricardi U; Munoz F; Reali A; Barone C; Musu AR; Balcet V; Franco P; Grillo R; Bustreo S; Pecorari G; Cavalot A; Garzino Demo P; Ciuffreda L; Ragona R; Schena M
    Clin Oncol (R Coll Radiol); 2011 Mar; 23(2):134-40. PubMed ID: 21030225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute effects of accelerated radiotherapy in combination with carbogen breathing and nicotinamide (ARCON).
    Zackrisson B; Franzén L; Henriksson R; Littbrand B; Stratford M; Dennis M; Rojas AM; Denekamp J
    Acta Oncol; 1994; 33(4):377-81. PubMed ID: 8018369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reevaluation of the radiosensitizing effects of sanazole and nimorazole in vitro and in vivo.
    Sugie C; Shibamoto Y; Ito M; Ogino H; Suzuki H; Uto Y; Nagasawa H; Hori H
    J Radiat Res; 2005 Dec; 46(4):453-9. PubMed ID: 16394636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.
    Fu KK; Clery M; Ang KK; Byhardt RW; Maor MH; Beitler JJ
    Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):589-97. PubMed ID: 7790243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-life assessment of Volumetric Modulated Arc Therapy (VMAT) toxicity in Head and Neck Squamous Cell Carcinoma (HNSCC) treatment.
    Moncharmont C; Vallard A; Mengue Ndong S; Guy JB; Saget C; Méry B; Langrand-Escure J; de Laroche G; Goyet D; Prades JM; Fournel P; Magné N
    Acta Otolaryngol; 2016; 136(2):181-8. PubMed ID: 26503806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurotoxicity in a phase I trial of continuous infusion cisplatin with hyperfractionated radiotherapy for locally advanced head and neck cancer.
    Clamon GH; Baatz L; Hoffman HT; Hussey DH; Glascock M; McCulloch TM; Graham SM
    Head Neck; 1996; 18(3):236-41. PubMed ID: 8860764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concomitant chemoradiotherapy using carboplatin, tegafur-uracil and leucovorin for stage III and IV head-and-neck cancer: results of GORTEC Phase II study.
    Fesneau M; Pointreau Y; Chapet S; Martin L; Pommier P; Alfonsi M; Laguerre B; Feham N; Berger C; Garaud P; Calais G
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):154-63. PubMed ID: 19386430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial.
    Overgaard J; Mohanti BK; Begum N; Ali R; Agarwal JP; Kuddu M; Bhasker S; Tatsuzaki H; Grau C
    Lancet Oncol; 2010 Jun; 11(6):553-60. PubMed ID: 20382075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.